SEPREHVIR(R) (HSV1716), An Oncolytic Virus For Possible Treatment Of Malignant Pleural Mesothelioma: Phase I/IIa Clinical Study Underway As Of August 2013

SEPREHVIR(R) (HSV1716), An Oncolytic Virus For Possible Treatment Of Malignant Pleural Mesothelioma: Phase I/IIa Clinical Study Underway As Of August 2013

Virttu Biologics Limited, a UK biotechnology company, issued this press release in late August 2013, “Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR(R) Study in Mesothelioma.&#...

Close